Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tempus AI Cl A (TEM)

Tempus AI Cl A (TEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,161,721
  • Shares Outstanding, K 177,907
  • Annual Sales, $ 693,400 K
  • Annual Income, $ -705,810 K
  • EBIT $ -242 M
  • EBITDA $ -198 M
  • 60-Month Beta 5.22
  • Price/Sales 10.99
  • Price/Cash Flow N/A
  • Price/Book 22.88

Options Overview Details

View History
  • Implied Volatility 67.33% (+1.08%)
  • Historical Volatility 52.79%
  • IV Percentile 13%
  • IV Rank 9.11%
  • IV High 133.93% on 04/08/25
  • IV Low 60.65% on 12/10/25
  • Expected Move (DTE 7) 3.63 (5.56%)
  • Put/Call Vol Ratio 0.61
  • Today's Volume 22,126
  • Volume Avg (30-Day) 22,967
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 241,264
  • Open Int (30-Day) 329,268
  • Expected Range 61.69 to 68.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 5
  • High Estimate -0.25
  • Low Estimate -0.33
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +15.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.80 +11.09%
on 12/31/25
76.33 -14.42%
on 01/12/26
+0.60 (+0.93%)
since 12/23/25
3-Month
58.80 +11.09%
on 12/31/25
93.38 -30.05%
on 10/27/25
-21.72 (-24.95%)
since 10/23/25
52-Week
36.22 +80.34%
on 04/09/25
104.32 -37.38%
on 10/09/25
+10.48 (+19.11%)
since 01/23/25

Most Recent Stories

More News
Tempus Announces the Launch of Paige Predict

Following the acquisition of Paige in 2025, Tempus launches its new AI-powered, biomarker prediction solution for digital pathology

TEM : 65.32 (-4.45%)
Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology

Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation’s premier academic medical centers, today announced a multi-year strategic collaboration...

TEM : 65.32 (-4.45%)
Northwestern Medicine Selects Tempus to Expand Genomic Testing

Collaboration will focus on the oncology patient population

TEM : 65.32 (-4.45%)
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion

Reported preliminary, unaudited Data and application revenue of ~$316 million for the full year 2025, representing ~31% year-over-year growth, with Insights (data licensing) growing 38% ...

TEM : 65.32 (-4.45%)
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year...

TEM : 65.32 (-4.45%)
Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for presentation at the 2026 ASCO ...

TEM : 65.32 (-4.45%)
Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will participate in the 44th Annual J.P. Morgan Healthcare Conference, taking place January...

TEM : 65.32 (-4.45%)
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in November...

ONCY : 1.2400 (-2.36%)
SANA : 4.83 (-3.40%)
ABSI : 2.91 (-7.91%)
RXRX : 4.73 (-4.64%)
TEM : 65.32 (-4.45%)
Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio...

TEM : 65.32 (-4.45%)
5 Tech Stocks Insiders Are Selling (But Smart Investors Are Loading Up)

Insiders are selling tech stocks after the massive rally in 2025. Some are up by 300% or more, providing attractive exits for execs. Investors shouldn't follow.

CRWV : 92.98 (+1.30%)
CRDO : 133.16 (-1.44%)
JBL : 243.14 (-0.64%)
STX : 346.10 (-0.12%)
TEM : 65.32 (-4.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery,...

See More

Key Turning Points

3rd Resistance Point 72.01
2nd Resistance Point 70.48
1st Resistance Point 67.90
Last Price 65.32
1st Support Level 63.79
2nd Support Level 62.26
3rd Support Level 59.68

See More

52-Week High 104.32
Fibonacci 61.8% 78.31
Fibonacci 50% 70.27
Last Price 65.32
Fibonacci 38.2% 62.23
52-Week Low 36.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar